A compound of Formula (VIII): wherein X 1 is O, NH, S, CH 2, or CF 2; R 1 and R 2 are independently selected from hydrogen, halo, C 1-6 alkyl, and C 1-6 haloalkyl; R 3 is selected from halo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, cyano, and nitro; n is a number from zero to 4; R 4 is selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, and -NR 12 R 23; w herein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and each R 22 and R 23 are independently selected from hydrogen and C 1-6 alkyl or R 22 and R 23 may be joined to form a 3 to 10 membered ring; R 5 is selected from hydrogen and C 1-6 alkyl; R 6 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; R 7 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; R 8 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; Q is CR 9 or N; where R 9 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; R 11 is selected from hydrogen and C 1-6 alkyl; R 12 is selected from hydrogen and C 1-6 alkyl; R 13 is selected from hydrogen, C 1-6 alkyl, C 1-6 acyl, SO 2 -C 1-6 alkyl, C 3-7 cycloalkyl, and C 6-20 aryl, wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C 1-6 alkoxy, or halo; and - NR 18 R 19 is (a) wherein R 10 is selected from hydrogen and C 1-6 alkyl; R 15 is unsubstituted methyl, or is C 2-4 alkyl unsubstituted or substituted with hydroxy, methoxy, or halo; and m is 1 or 2; or is (b) where R 19 and R 9 taken together form a 5- or 6-membered heteroaryl ring optionally substituted with C 1-6 alkyl that is unsubstituted or substituted with amino, hydroxyl, or halo; and R 18 is hydrogen or C 1-6 alkyl, or is absent to satisfy valency of the heteroaryl ring; provided that neither of R 6 or R 7 is methoxy when -NR 18 R 19 is or a pharmaceutically acceptable salt thereof. X 1 is O, NH, S, CH 2, or CF 2; R 1 and R 2 are independently selected from hydrogen, halo, C 1-6 alkyl, and C 1-6 haloalkyl; R 3 is selected from halo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, cyano, and nitro; n is a number from zero to 4; R 4 is selected from hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, and -NR 12 R 23; w herein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and each R 22 and R 23 are independently selected from hydrogen and C 1-6 alkyl or R 22 and R 23 may be joined to form a 3 to 10 membered ring; herein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and each R 22 and R 23 are independently selected from hydrogen and C 1-6 alkyl or R 22 and R 23 may be joined to form a 3 to 10 membered ring; R 5 is selected from hydrogen and C 1-6 alkyl; R 6 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; R 7 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; R 8 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; Q is CR 9 or N; where R 9 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; where R 9 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, hydroxyl, cyano, and nitro; R 11 is selected from hydrogen and C 1-6 alkyl; R 12 is selected from hydrogen and C 1-6 alkyl; R 13 is selected from hydrogen, C 1-6 alkyl, C 1-6 acyl, SO 2 -C 1-6 alkyl, C 3-7 cycloalkyl, and C 6-20 aryl, wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C 1-6 alkoxy, or halo; and - wherein each alkyl or aryl is unsubstituted or substituted with hydroxyl, C 1-6 alkoxy, or halo; and - NR 18 R 19 is (a) wherein R 10 is selected from hydrogen and C 1-6 alkyl; R 15 is unsubstituted methyl, or is C 2-4 alkyl unsubstituted or substituted with hydroxy, methoxy, or halo; and m is 1 or 2; or is (b) where R 19 and R 9 taken together form a 5- or 6-membered heteroaryl ring optionally substituted with C 1-6 alkyl that is unsubstituted or substituted with amino, hydroxyl, or halo; and R 18 is hydrogen or C 1-6 alkyl, or is absent to satisfy valency of the heteroaryl ring; (a) wherein R 10 is selected from hydrogen and C 1-6 alkyl; R 15 is unsubstituted methyl, or is C 2-4 alkyl unsubstituted or substituted with hydroxy, methoxy, or halo; and m is 1 or 2; or is wherein R 10 is selected from hydrogen and C 1-6 alkyl; R 15 is unsubstituted methyl, or is C 2-4 alkyl unsubstituted or substituted with hydroxy, methoxy, or halo; and m is 1 or 2; (b) where R 19 and R 9 taken together form a 5- or 6-membered heteroaryl ring optionally substituted with C 1-6 alkyl that is unsubstituted or substituted with amino, hydroxyl, or halo; and R 18 is hydrogen or C 1-6 alkyl, or is absent to satisfy valency of the heteroaryl ring; provided that neither of R 6 or R 7 is methoxy when -NR 18 R 19 is or a pharmaceutically acceptable salt thereof.